Valbiotis SA (EPA:ALVAL)

France flag France · Delayed Price · Currency is EUR
1.070
-0.022 (-2.01%)
Apr 2, 2026, 5:35 PM CET
Market Cap25.31M +43.3%
Revenue (ttm)905.00K +414.2%
Net Income-9.42M
EPS-0.47
Shares Out23.66M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume77,294
Average Volume154,270
Open1.090
Previous Close1.092
Day's Range1.050 - 1.092
52-Week Range0.535 - 1.296
Beta-0.21
RSI55.66
Earnings DateJun 26, 2026

About Valbiotis

Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort. It also develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis. Valbioti... [Read more]

Founded 2014
Employees 50
Stock Exchange Euronext Paris
Ticker Symbol ALVAL
Full Company Profile

Financial Performance

In 2025, Valbiotis's revenue was 905,000, an increase of 414.20% compared to the previous year's 176,000. Losses were -9.42 million, -6.06% less than in 2024.

Financial Statements